Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.9450 (-0.31%) ($12.9450 - $12.9450) on Wed. Aug. 16, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.47% (three month average) | RSI | 48 | Latest Price | $12.9450(-0.31%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.1% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(66%) IBB(60%) ARKG(55%) IWO(43%) BWX(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.235% in a week (0% probabilities). TBT(-35%) UUP(-16%) VXX(-8%) URA(-1%) EDOC(-0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.235% (StdDev 2.47%) | Hourly BBV | -0.8 () | Intraday Trend | 0% | | | |
|
Resistance Level | $13.36 | 5 Day Moving Average | $13.18(-1.78%) | 10 Day Moving Average | $13.25(-2.3%) | 20 Day Moving Average | $13.36(-3.11%) | To recent high | -6.1% | To recent low | 20.5% | Market Cap | $3.343b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |